Answers are grounded in this paper and cite their sources.
Review summarizes epidemiological patterns and transmission pathways of ESBL-Ec in communities, highlighting public health implications.
SUMMARY Since the worldwide dissemination of extended-spectrum β-lactamase-producing Escherichia coli (ESBL-Ec) in the early 2000s, ESBL-Ec community carriage has followed divergent epidemiological patterns across regions. Currently, high-income countries (HIC) have a lower prevalence of ESBL-Ec carriage compared to the more concerning prevalence observed in low- and middle-income countries (LMICs). The aim of this review is to summarize the factors that could explain variations in ESBL-Ec prevalence by bridging together information from epidemiological, clinical, and bacterial genetic data. First, geographical differences in ESBL-Ec carriage in the community could be partly related to disparities in socioeconomic levels (e.g., country-level income, Human Development Index) and their associated conditions. Few risk factors associated with ESBL-Ec carriage overlap between LMICs and HICs, except for antibiotic use. Transmission across human, animal, and environmental sectors is much more common in LMICs, whereas inter-human transmission in HICs is more prominent. From the available molecular data, distinct bacterial genetic backgrounds between LMICs (predominantly A and B1 E. coli phylogroups) and HICs (predominantly B2 phylogroup) highlight the clones able to successfully disseminate in these settings. As the dissemination of ESBL-Ec is driven by a complex interplay of socioeconomic, behavioral, and bacterial genetic factors, tailored public health strategies, including antibiotic stewardship and innovative strategies discussed herein, are essential to curb further increases in their prevalence.
No takes yet. Share an insight, caveat, or question.
Beaumont et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: